DDIT3 and diffuse large B-cell lymphoma: The PHOENIX trial found no improvement in event-free survival by adding ibrutinib to R-CHOP in patients with newly diagnosed non-GCB DLBCL, and ibrutinib plus R-CHOP was associated with increased toxicity in patients >60 years old, leading to compromised R-CHOP administration and worse outcomes [3].